FAQ Library

FAQ Library published on December 11, 2017
Dr. Khorana discusses the role of neoadjuvant chemotherapy in pancreatic cancer.
FAQ Library published on November 6, 2017
Dr. Ramanathan discusses ongoing clinical trials in both front-line and second-line therapy for advanced metastatic pancreatic cancer, including immuno-oncology studies.
FAQ Library published on October 23, 2017
Dr. Khorana discusses the role of a multidisciplinary team in deciding which pancreatic cancer patients should be offered the option of tumor resection, and the process by which that decision is made.
FAQ Library published on October 9, 2017
Dr. Bekaii-Saab discusses new options for first-, second- and third-line therapy in advanced metastatic pancreatic cancer, as well as factors that must be considered in selecting among these agents.
FAQ Library published on September 11, 2017
Join Dr. Ramanathan as he discusses oxaliplatin for the treatment of advanced metastatic pancreatic cancer in second-line therapy.
FAQ Library published on August 7, 2017
Dr. Bekaii-Saab discusses the key points that community providers should consider when determining the best treatment approach for patients with advanced metastatic pancreatic cancer.
FAQ Library published on July 10, 2017
Join Dr. Ramanathan as he discusses the role immunotherapy will have in advanced pancreatic cancer, including the potential for combination therapy and which agents are already approved.
FAQ Library published on June 13, 2017
Dr. Bekaii-Saab discusses emerging agents that are designed to target the stroma in patients with advanced metastatic pancreatic cancer.
FAQ Library published on December 7, 2016
Dr. Bruera provides insight into the best practices for talking with your patients with advanced cancer.
FAQ Library published on November 9, 2016
Are you wondering about the current status of adjuvant therapy in patients who undergo resection for pancreatic cancer? Dr. Margaret A. Tempero provides an answer to this frequently asked question.
Page 1 of 6
Results 1 - 10 of 52

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2018 MediCom Worldwide, Inc. All rights reserved